- Home
- QLYS vs ACLX Comparison
QLYS vs ACLX Comparison
Compare QLYS & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$104.92
HOLD
Current Price
$68.61
Company Overview
Basic Information| Metric | QLYS | ACLX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.7B |
| IPO Year | 2012 | 2022 |
Fundamental Metrics
Financial Performance| Metric | QLYS | ACLX |
|---|---|---|
| Price | $104.92 | $68.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $138.07 | $113.75 |
| AVG Volume (30 Days) | 704.0K | ★ 868.4K |
| Earning Date | 02-05-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.99 | N/A |
| EPS | ★ 5.44 | N/A |
| Revenue | ★ $669,125,000.00 | $35,898,000.00 |
| Revenue This Year | $9.51 | N/A |
| Revenue Next Year | $6.69 | $309.32 |
| P/E Ratio | $19.28 | ★ N/A |
| Revenue Growth | ★ 10.13 | N/A |
| 52 Week Low | $104.22 | $47.86 |
| 52 Week High | $155.47 | $94.07 |
Technical Indicators
Market Signals| Indicator | QLYS | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 24.99 | 55.39 |
| Support Level | $107.17 | $66.12 |
| Resistance Level | $114.34 | $70.34 |
| Average True Range (ATR) | 6.15 | 2.60 |
| MACD | -2.40 | 0.20 |
| Stochastic Oscillator | 2.23 | 83.43 |
Price Performance
Historical Comparison QLYS
ACLX
About QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.